Brad White is a partner in the firm's Ottawa office and chair of the national IP department at Osler. He practises IP law with an emphasis on complex patent litigation and patent prosecution. He provides clients with strategic advice on the enforcement of their patent rights, including the management of litigation strategies throughout multiple jurisdictions, instructing foreign counsel in litigation and having carriage of worldwide IP portfolios. Brad has appeared as lead counsel before the Federal Court of Appeal, the Federal Court and the Ontario Superior Court, and has appeared before the US International Trade Commission in the role of coordinating worldwide litigation and IP counsel. He is also a registered patent agent and specialises in Canadian and foreign patent and industrial design prosecution; strategic reviews of IP portfolios; patentability, patent infringement and validity opinions; and worldwide patent portfolio management and enforcement.
Brad is recognised internationally as a leading patent litigator and IP practitioner, including in the IAM Patent 1000 (since 2012); The Best Lawyers in Canada for IP law – patent and litigation (since 2011); Chambers Global, The World's Leading Lawyers for Business 2017 (IP litigation and intellectual property); the Canadian Legal Lexpert Directory 2016 (intellectual property and IP litigation); the Lexpert Guide to the Leading US/Canada Cross-Border Litigation Lawyers 2016; Benchmark Litigation Canada (Ontario Litigation Star for Intellectual Property) 2016; Managing Intellectual Property 2016 (IP Star – Canada); in both the IAM Patent Litigation 250 (2011) and Life Sciences 250 (2010); and the latest Expert Guide for Patent Practitioners.
Brad is also registered to practise before the US Patent and Trademark Office and is a former associate editor of the Canadian Patent Reporter. He has been involved in many notable matters for some of the world's leading corporations, including as lead outside counsel to Mylan Pharmaceuticals ULC in connection with patent and numerous pharmaceutical and general litigation matters. Recently, as lead counsel, Brad successfully represented Mylan Pharmaceuticals in three successive victories in patent proceedings including in AstraZeneca Canada Inc. v Mylan Pharmaceuticals ULC, 2017 FC 142. On February 7, 2017, the Federal Court of Canada issued a decision that invalidated the Canadian formulation patent relating to VIMOVO®. Canadian patients will be the first in the world to benefit from a generic version of this drug.
- Intellectual Property Institute of Canada
- American Intellectual Property Law Association
- International Association for the Protection of Intellectual Property (AIPPI)
- Canadian Bar Association